Welcome to our dedicated page for Tscan Therapeutics news (Ticker: TCRX), a resource for investors and traders seeking the latest updates and insights on Tscan Therapeutics stock.
TScan Therapeutics, Inc. (NASDAQ: TCRX) is a pioneering biopharmaceutical company focused on developing advanced T-cell receptor (TCR) engineered T cell therapies (TCR-T) aimed at treating cancer. Specializing in harnessing novel T cell systems, TScan is at the forefront of extending the promise of immunotherapy to patients with hematologic malignancies and solid tumors.
The company's leading therapies, TSC-100 and TSC-101, are designed to eliminate residual leukemia and prevent relapse in patients with blood cancers such as acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) undergoing hematopoietic stem cell transplantation. These liquid tumor TCR-T therapy candidates are currently in development, reflecting TScan's commitment to improving patient outcomes.
TScan is also developing multiplexed TCR-T therapy candidates for treating various solid tumors, showcasing the company's versatility and innovative approach in the immunotherapy landscape. Recent recognition includes the RMAT designation granted for both TSC-100 and TSC-101, highlighting their potential significance in cancer treatment.
In addition to its groundbreaking therapeutic developments, TScan Therapeutics maintains strong partnerships and a robust financial foundation. The company frequently updates its stakeholders through transparent communication and investor relations, ensuring that all relevant developments and milestones are promptly shared.
For the latest news and updates, you can contact Heather Savelle, VP of Investor Relations, at 857-399-9840 or via email at hsavelle@tscan.com. Further inquiries can also be directed to Joyce Allaire, Managing Director at LifeSci Advisors, LLC, at 617-435-6602 or jallaire@lifesciadvisors.com.
TScan Therapeutics, Inc. (TCRX) announced the appointment of Dr. Barbara Klencke to its Board of Directors, effective April 6, 2023. With over 20 years of oncology drug development experience, Dr. Klencke's expertise will enhance the company's clinical and commercial strategies as it advances its T cell receptor-engineered therapies for cancer. Key leadership promotions were also unveiled, with Shrikanta Chattopadhyay, Ann Hargraves, and Ray Lockard stepping up to Senior Vice President roles in Medical, Human Resources, and Technical Operations, respectively. These changes aim to strengthen TScan's operational capabilities and support ongoing clinical trials targeting hematologic malignancies and solid tumors throughout 2023.
TScan Therapeutics, Inc. (Nasdaq: TCRX) announced the appointment of Gavin MacBeath, Ph.D., as acting CEO, effective March 28, 2023, following the resignation of David Southwell. MacBeath, who has been with TScan since 2018 and has extensive experience in academia and industry, will continue to lead the company's clinical programs, including the recently dosed patient for TSC-101. TScan reports progress in clinical trials for hematologic malignancies and solid tumors, with plans for patient enrollment in the second quarter of 2023. As of December 31, 2022, the company had $120 million in cash, sufficient to fund operations into Q2 2024.
FAQ
What is the current stock price of Tscan Therapeutics (TCRX)?
What is the market cap of Tscan Therapeutics (TCRX)?
What is TScan Therapeutics, Inc.?
What are TScan's leading therapy candidates?
What recent recognition has TScan's therapies received?
What types of cancer does TScan focus on?
How does TScan aim to improve cancer treatment?
How can I contact TScan's Investor Relations?
Where can I get the latest updates about TScan?
What is the stock symbol for TScan Therapeutics, Inc.?
Who are the key contacts for media inquiries at TScan?
What are TScan's goals in immunotherapy?
